• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

    95.98 +2.78 (+2.98%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 463,293
    Open 91.64
    Bid (Size) 95.00 (1,000)
    Ask (Size) 96.00 (100)
    Prev. Close 93.21
    Today's Range 79.50 - 99.71
    52wk Range 23.18 - 123.75
    Shares Outstanding 11,834,361
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    The market is filled with gapping stocks in Wednesday's session. ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Tuesday's session. ↗
    Via Chartmill

    Performance

    YTD
    +15.0%
    +15.0%
    1 Month
    +18.3%
    +18.3%
    3 Month
    +88.8%
    +88.8%
    6 Month
    +259.0%
    +259.0%
    1 Year
    +131.8%
    +131.8%

    More News

    Read More
    News headline image
    Why Did DRUG Stock Rocket 51% Today? ↗
    Via Stocktwits
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Why Bright Minds Biosciences Stock Topped the Market on Monday ↗
    Via The Motley Fool
    News headline image
    Large Patient Population Is Key Driver For Bright Minds' Growth ↗
    Via Benzinga
    News headline image
    Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside ↗
    Via Benzinga
    News headline image
    Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Biotechs on the Brink: 2 Stocks With Huge Potential
    Via MarketBeat
    News headline image
    This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
    Via Benzinga
    News headline image
    Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month ↗
    Via The Motley Fool
    News headline image
    Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗
    Via Benzinga
    Topics Government
    News headline image
    What's Going On With Bright Minds Biosciences Stock? ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    MarketBeat Week in Review – 10/14 - 10/18
    Via MarketBeat
    Topics Artificial Intelligence Economy
    News headline image
    Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results ↗
    Via Benzinga
    News headline image
    What's Going On With Bright Minds Biosciences Stock Friday? ↗
    Via Benzinga
    News headline image
    Dow Falls Over 100 Points; Netflix Posts Upbeat Results ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis ↗
    Via Benzinga
    Topics Artificial Intelligence
    Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF
    Via AB Newswire
    News headline image
    Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views ↗
    Via Benzinga
    Topics Stocks

    Frequently Asked Questions

    Is Bright Minds Biosciences Inc. - common stock publicly traded?
    Yes, Bright Minds Biosciences Inc. - common stock is publicly traded.
    What exchange does Bright Minds Biosciences Inc. - common stock trade on?
    Bright Minds Biosciences Inc. - common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Bright Minds Biosciences Inc. - common stock?
    The ticker symbol for Bright Minds Biosciences Inc. - common stock is DRUG on the Nasdaq Stock Market
    What is the current price of Bright Minds Biosciences Inc. - common stock?
    The current price of Bright Minds Biosciences Inc. - common stock is 95.98
    When was Bright Minds Biosciences Inc. - common stock last traded?
    The last trade of Bright Minds Biosciences Inc. - common stock was at 01/07/26 04:00 PM ET
    What is the market capitalization of Bright Minds Biosciences Inc. - common stock?
    The market capitalization of Bright Minds Biosciences Inc. - common stock is 1.14B
    How many shares of Bright Minds Biosciences Inc. - common stock are outstanding?
    Bright Minds Biosciences Inc. - common stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.